MedPath

Bioequivalence study of Sitagliptin 50 mg Metformin Hydrochloride 500 mg extended release Tablets in healthy adult human subjects under fasting conditions

Not Applicable
Registration Number
CTRI/2023/04/052085
Lead Sponsor
SunGlow Lifescience Private limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Able to comprehend the nature and purpose of the study and willing to give written informed consent for participation in the study

2 Willing to be available for the entire study period and to comply with protocol requirements

3 Normal healthy adult human subject of 18 45 years both inclusive of age

4 Body mass index in the range of 18 30 kg m2 both inclusive

5 Healthy volunteers who are clinically non anemic will be included as per the discretion of PI/CI/Physician

Exclusion Criteria

1 Any medical or surgical condition which might significantly interfere with the functioning of the gastrointestinal tract or blood forming organs

2 History or presence of gastric or duodenal ulcer or GI bleeding or blood in stools anytime in the past

3 History of severe infection or major surgery in the past 6 months

4 History of Minor surgery or fracture within the past 3 months

5 Significant history or current evidence of malignancy or chronic infectious cardiovascular renal, hepatic ophthalmic pulmonary neurological metabolic endocrine hematological gastrointestinal immunological or psychiatric diseases or organ dysfunction

Study & Design

Study Type
BA/BE
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath